A Phase 3 interventional study of Orforglipron in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 40 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 6 that started in 2023, is one of 11 in phase 3, and was the 7th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in India, Saudi Arabia, South Africa and 1 more country
Ages 18–65
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 8 more countries
Ages 10–17
Massachusetts General Hospital
Ages 18–79
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 6 started in 2023.
This study's enrollment of 401 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 546 across the 15 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 74th largest by enrollment of the 232 interventional ones that give a count, is one of 17 that started in 2023, is one of 85 in phase 3, and was the 201st registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing orforglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613307Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | 2027-05 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the long-term safety of the study intervention orforglipron as a monotherapy or in combination with oral antihyperglycemic medication.
This study includes 3 periods as follows:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have had any of the following cardiovascular (CV) conditions within 60 days prior to screening, or between screening and randomization.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received once-daily oral orforglipron for 52 weeks. Treatment began with a 1-mg loading dose for the first 4 weeks, followed by the maintenance dose of 3 mg for the remainder of the duration.
Drug: Orforglipron
Participants received once-daily oral orforglipron for 52 weeks. Treatment began with a 1-mg loading dose for the first 4 weeks, followed by dose escalations every 4 weeks to reach the maintenance dose of 12 mg at week 12, which was then continued for the remainder of the duration.
Drug: Orforglipron
Participants received once-daily oral orforglipron for 52 weeks. Treatment began with a 1-mg loading dose for the first 4 weeks, followed by dose escalations every 4 weeks to reach the maintenance dose of 36 mg at week 20, which was then continued for the remainder of the duration.
Drug: Orforglipron
Administered orally
Also known as: LY3502970
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.
Time frame: Baseline to Week 54
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Baseline, Week 52
Percentage of Participants Who Achieved HbA1c <7.0%
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
Time frame: Week 52
Percentage of Participants Who Achieved HbA1c ≤6.5%
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
Time frame: Week 52
Percentage of Participants Who Achieved HbA1c <5.7%
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
Time frame: Week 52
Change From Baseline in Fasting Serum Glucose
Time frame: Baseline, Week 52
Change From Baseline in Body Weight
Time frame: Baseline, Week 52
Percentage of Participants Who Achieved Weight Loss of ≥5% From Baseline
The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
Time frame: Week 52
Percentage of Participants Who Achieved Weight Loss of ≥10% From Baseline
The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
Time frame: Week 52
Percentage of Participants Who Achieved Weight Loss of ≥15% From Baseline
The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
Time frame: Week 52
Change From Baseline in Waist Circumference
Time frame: Baseline, Week 52
Change From Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 52
Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG)
SMBG is measured using a glucometer. The SMBG profiles will consist of the following 7-point measurements obtained on a single day: * before 3 main meals, * approximately 2 hours after 3 main meals, and * at bedtime Daily average glucose was calculated as the mean of 7 time point specific averages obtained from up to 2 non-consecutive SMBG profiles within week 52.
Time frame: Baseline, Week 52
| Milestone | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Started | 132 | 135 | 134 |
| Received at least one dose of study drug | 132 | 135 | 134 |
| Completed | 125 | 128 | 125 |
| Not completed | 7 | 7 | 9 |
| Withdrew: Adverse event | 2 | 6 | 3 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 5 |
A TEAE was defined as any adverse event that began on or after the first dose of study drug or began before the first dose of study drug and worsened on or after the first dose of study drug.
| Participants | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 107 | 114 | 118 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
| percentage of HbA1c | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -1.71 ± 0.072 | -1.97 ± 0.075 | -2.13 ± 0.073 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
| percentage of participants | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c <7.0% | 82.73 ± 3.25 | 86.11 ± 2.86 | 90.82 ± 2.52 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
| percentage of participants | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c ≤6.5% | 62.64 ± 4.11 | 76.23 ± 3.57 | 84.56 ± 3.27 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
| percentage of participants | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c <5.7% | 7.70 ± 2.20 | 21.92 ± 3.54 | 30.51 ± 3.86 |
| milligrams per deciliter (mg/dL) | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose | -51.7 ± 1.40 | -55.1 ± 2.86 | -64.5 ± 1.37 |
| kilogram (kg) | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Change From Baseline in Body Weight | -1.81 ± 0.307 | -5.08 ± 0.474 | -6.75 ± 0.509 |
The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
| percentage of participants | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss of ≥5% From Baseline | 27.00 ± 3.90 | 49.52 ± 4.40 | 65.14 ± 4.24 |
The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
| percentage of participants | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss of ≥10% From Baseline | 10.11 ± 2.66 | 24.68 ± 3.78 | 37.91 ± 4.30 |
The reported values represent model-based estimates. The Mean (SE) is an estimated values from a logistic regression using imputed data by multiple imputation, with percentages derived by combining proportion of participants achieving target in imputed data sets using Rubin's rule.
| percentage of participants | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss of ≥15% From Baseline | 2.79 ± 1.46 | 13.96 ± 3.07 | 20.94 ± 3.66 |
| centimeter (cm) | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Change From Baseline in Waist Circumference | -2.4 ± 0.43 | -4.6 ± 0.49 | -6.5 ± 0.54 |
| kilogram per square meter (kg/m^2) | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) | -0.7 ± 0.12 | -1.9 ± 0.17 | -2.5 ± 0.19 |
SMBG is measured using a glucometer. The SMBG profiles will consist of the following 7-point measurements obtained on a single day: * before 3 main meals, * approximately 2 hours after 3 main meals, and * at bedtime Daily average glucose was calculated as the mean of 7 time point specific averages obtained from up to 2 non-consecutive SMBG profiles within week 52.
| mg/dL | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Change From Baseline in Daily Average 7-Point Self-Monitored Blood Glucose (SMBG) | -66.32 ± 40.622 | -73.14 ± 41.064 | -82.27 ± 39.367 |
Collected over Baseline to Week 54. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 3 mg Orforglipron | 0/132 (0%) | 4/132 (3%) | 106/132 (80.3%) |
| 12 mg Orforglipron | 0/135 (0%) | 3/135 (2.2%) | 114/135 (84.4%) |
| 36 mg Orforglipron | 1/134 (0.7%) | 6/134 (4.5%) | 118/134 (88.1%) |
| Event | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/93 | 0/97 | 1/93 |
| PeriodontitisInfections and infestations | 1/132 | 0/135 | 0/134 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 1/132 | 0/135 | 0/134 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/132 | 0/135 | 0/134 |
| LipomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/132 | 0/135 | 0/134 |
| Aortic stenosisVascular disorders | 1/132 | 0/135 | 0/134 |
| CholecystocholangitisHepatobiliary disorders | 0/132 | 0/135 | 1/134 |
| Enterocolitis bacterialInfections and infestations | 0/132 | 0/135 | 1/134 |
| Humerus fractureInjury, poisoning and procedural complications | 0/132 | 0/135 | 1/134 |
| DehydrationMetabolism and nutrition disorders | 0/132 | 0/135 | 1/134 |
| Event | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 22/132 | 41/135 | 39/134 |
| NauseaGastrointestinal disorders | 17/132 | 26/135 | 37/134 |
| NasopharyngitisInfections and infestations | 23/132 | 30/135 | 22/134 |
| DyspepsiaGastrointestinal disorders | 8/132 | 10/135 | 18/134 |
| VomitingGastrointestinal disorders | 17/132 | 15/135 | 17/134 |
| DiarrhoeaGastrointestinal disorders | 12/132 | 16/135 | 16/134 |
| Decreased appetiteMetabolism and nutrition disorders | 3/132 | 6/135 | 13/134 |
| Covid-19Infections and infestations | 12/132 | 11/135 | 11/134 |
| Gastrointestinal disorderGastrointestinal disorders | 11/132 | 5/135 | 7/134 |
| Abdominal discomfortGastrointestinal disorders | 10/132 | 6/135 | 7/134 |
All participants who were randomized and received at least one dose of the study drug.
| Age, Continuous(years) | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|
| Mean | 59.9 ± 10.3 | 58.5 ± 11.0 | 57.5 ± 10.7 | 58.6 ± 10.7 |
| Sex: Female, Male(Participants) | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|
| Female | 39 | 38 | 41 | 118 |
| Male | 93 | 97 | 93 | 283 |
| Ethnicity (NIH/OMB)(Participants) | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 132 | 135 | 134 | 401 |
| Race (NIH/OMB)(Participants) | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 132 | 135 | 134 | 401 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 3 mg Orforglipron | 12 mg Orforglipron | 36 mg Orforglipron | Total |
|---|---|---|---|---|
| Japan | 132 | 135 | 134 | 401 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2023 to primary completion in Jun 2025, 20 months.
Results were first posted in Jun 2026, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 20 months is close to that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron